IP Library › Granted Patent US 12,241,105
Granted Patent B2
US 12,241,105 · App. 17/813,240 · Granted Mar 4, 2025

Recombinant microorganisms and uses therefor

Inventors: Nicholas Alexander Fackler (Chicago, IL); Sean Dennis Simpson (Evanston, IL); Michael Koepke (Chicago, IL); Stephanie Rhianon Jones (Evanston, IL)
Assignee: LanzaTech, Inc.
C12P19/34C12N1/20C12N1/32C12P7/04G16B5/10G16B20/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,241,105
App. No.
17/813,240
Granted
Mar 4, 2025
Kind
B2
Abstract

The disclosure provides genetically engineered C1-fixing microorganisms capable of producing nanobodies. Additionally, the disclosure provides engineered microorganisms comprising one or more disrupted genes to strategically divert carbon flux away from nonessential or undesirable products towards products and/or co-products of interest. The disclosure enables co-production of useful chemicals from gaseous substrates.

Claims (8)

1. A genetically engineered C1-fixing microorganism capable of co-producing at least one target product and a nanobody comprising an exogenous nucleic acid encoding a nanobody gene, wherein the genetically engineered C1-fixing microorganism has improved carbon flux through acetoacetyl-CoA compared to a parental microorganism, wherein the nanobody gene is VHH-72 SARS Cov2.

2. The genetically engineered C1-fixing microorganism of claim 1 , wherein the at least one target product is selected from the group 1-butanol, butyrate, butene, butadiene, methyl ethyl ketone, ethylene, acetone, isopropanol, lipids, 3-hydroxypropionate, terpenes, isoprene, fatty acids, 2-butanol, 1,2-propanediol, 1-propanol, 1-hexanol, 1-octanol, chorismate-derived products, 3-hydroxybutyrate, 1,3-butanediol, 2-hydroxyisobutyrate or 2-hydroxyisobutyric acid, isobutylene, adipic acid, keto-adipic acid, 1,3-hexanediol, 3-methyl-2-butanol, 2-buten-1-ol, isovalerate, isoamyl alcohol, and monoethylene glycol.

3. The genetically engineered C1-fixing microorganism of claim 1 , wherein the nanobody is contained in the microorganism.

4. The genetically engineered C1-fixing microorganism of claim 1 , further comprising a disruptive mutation in one or more genes.

5. The genetically engineered C1-fixing microorganism of claim 1 , wherein the parental microorganism is selected from the group consisting of Acetobacterium woodii, Alkalibaculum bacchii, Blautia producta, Butyribacterium methylotrophicum, Clostridium aceticum, Clostridium autoethanogemum, Clostridium carboxidivorans, Clostridium coskatii, Clostridium drakei, Clostridium formicoaceticum, Clostridium ljungdahlii, Clostridium magmnum, Clostridium ragsdalei, Clostridium scatologenes, Eubacterium limosum, Moorella thermautotrophica, Moorella thermoacetica, Oxobacter pfennigii, Sporomusa ovata, Sporomusa silvacetica, Sporomusa sphaeroides, Cupriavidus necator and Thermoanaerobacter kivui.

6. The genetically engineered C1-fixing microorganism of claim 1 , wherein the parental microorganism is selected from the group consisting of Clostridium autoethanogemum, Clostridium ljungdahlii , and Clostridium ragsdalei.

7. A method of co-producing at least one target product and a nanobody by culturing the genetically engineered C1-fixing microorganism of claim 1 in the presence of a gaseous substrate comprising one or more of CO, CO 2 , and H 2 .

8. The method of claim 7 , wherein the at least one target product is selected from the group 1-butanol, butyrate, butene, butadiene, methyl ethyl ketone, ethylene, acetone, isopropanol, lipids, 3-hydroxypropionate, terpenes, isoprene, fatty acids, 2-butanol, 1,2-propanediol, 1-propanol, 1-hexanol, 1-octanol, chorismate-derived products, 3-hydroxybutyrate, 1,3-butanediol, 2-hydroxyisobutyrate or 2-hydroxyisobutyric acid, isobutylene, adipic acid, keto-adipic acid, 1,3-hexanediol, 3-methyl-2-butanol, 2-buten-1-ol, isovalerate, isoamyl alcohol, or monoethylene glycol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2022
From: FACKLER, NICHOLAS ALEXANDER; SIMPSON, SEAN DENNIS; KOEPKE, MICHAEL; JONES, STEPHANIE RHIANON
To: LANZATECH, INC.
Reel/Frame 060842/0239 →
Continuity (2)
Provisional Application 63223952 · Jul 20, 2021
Related Publication 20230129301A1 · Apr 27, 2023
References Cited (59)
US 5593886A · Gaddy · 1997 [cited by applicant]
US 6368819B1 · Gaddy et al. · 2002 [cited by applicant]
US 7704723B2 · Huhnke · 2010 [cited by applicant]
US 7972824B2 · Simpson · 2011 [cited by applicant]
US 8222013B2 · Simpson · 2012 [cited by applicant]
US 8293509B2 · Simpson · 2012 [cited by applicant]
US 8658408B2 · Simpson · 2014 [cited by applicant]
US 8900836B2 · Simpson · 2014 [cited by applicant]
US 9068202B2 · Tran · 2015 [cited by applicant]
US 9284564B2 · Mueller · 2016 [cited by applicant]
US 9347076B2 · Liew · 2016 [cited by applicant]
US 9359611B2 · Koepke · 2016 [cited by applicant]
US 9410130B2 · Koepke · 2016 [cited by applicant]
US 9738875B2 · Koepke · 2017 [cited by applicant]
US 9890384B2 · Mueller · 2018 [cited by applicant]
US 9994878B2 · Koepke · 2018 [cited by applicant]
US 10174303B2 · Behrendorff · 2019 [cited by applicant]
US 10494600B2 · Heijstra · 2019 [cited by applicant]
US 10590406B2 · Koepke · 2020 [cited by applicant]
US 10913958B2 · Koepke · 2021 [cited by applicant]
US 20080107601A1 · Lauwereys et al. · 2008 [cited by applicant]
US 20120045807A1 · Simpson · 2012 [cited by applicant]
US 20130157322A1 · Simpson · 2013 [cited by applicant]
US 20160244785A1 · Koepke · 2016 [cited by applicant]
US 20190185888A1 · Koepke · 2019 [cited by applicant]
US 20210292732A1 · Liew · 2021 [cited by applicant]
US 20230050887A1 · Fackler · 2023 [cited by examiner]
KR 20120112254A · 2012 [cited by applicant]
WO 2021072399A1 · 2021 [cited by applicant]
Wellner et al. (Rapid generation of potent antibodies by autonomous hypermutation in yeast. Nature Chemical Biology (Epub Jul. 1, 2021), 17: 1057-1064) (Year: 2021). [cited by examiner]
Whisstock et al. Quaterly Reviews of Biophysics, 2003, “Prediction of protein function from protein sequence and structure”, 36(3): 307-340. (Year: 2003). [cited by examiner]
Witkowski et al. Conversion of a beta-ketoacyl synthase to a malonyl decarboxylase by replacement of the active-site cysteine with glutamine, Biochemistry. Sep. 7, 1999;38(36):11643-50. (Year: 1999). [cited by examiner]
Kisselev L., Polypeptide release factors in prokaryotes and eukaryotes: same function, different structure. Structure, 2002, vol. 10: 8-9. (Year: 2002). [cited by examiner]
Shin, Y. O., “Microorganisms for the production of monoclonal antibodies and antibody fragments”, ReSEAT Program, High-tech information analysis, 2014, pp. 1-5. (with English translation—total 12 pages). [cited by applicant]
Spadiut et al., “Microbials for the production of monoclonal antibodies and antibody fragments”, Trends in Biotechnology, 2014, vol. 32, No. 1, pp. 54-60. [cited by applicant]
International Search Report and Written Opinion issued in corresponding International Application No. PCT/US2022/073855 dated Nov. 11, 2022, 10 pages. [cited by applicant]
International Search Report and Written Opinion issued in corresponding International Application No. PCT/US2022/073858 dated Nov. 11, 2022, 11 pages. [cited by applicant]
Lee, Y. J. et al, “Challenges to production of antibodies in bacteria and yeast”, Journal of Bioscience and Bioengineering, 2015, vol. 120, No. 5, pp. 483-490. [cited by applicant]
Abrini, Arch Microbiol, 161: 345-351, 1994. [cited by applicant]
Cardoso et al. “Cameo: A Python Library for Computer Aided Metabolic Engineering and Optimization of Cell Factories,” ACS Synth. Biol. 2018, 7, 1163-1166. DOI: 10.1021/acssynbio.7b00423. [cited by applicant]
Drake, Acetogenic Prokaryotes, In: The Prokaryotes, 3rd edition, p. 354, New York, NY, 2006. [cited by applicant]
Ebrahim., COBRApy: COnstraints-Based Reconstruction and Analysis for Python, BMC Syst Biol, 7: 74, 2013. [cited by applicant]
Harmsen and Haard (2007) Appl. Microbiol. Biotechnol. 77 (1): 13-22. [cited by applicant]
Heap, J Microbiol Methods 78: 79-85, 2009. [cited by applicant]
Jensen, Optlang: An Algebraic Modeling Language for Mathematical Optimization, The Journal of Open Source Software, 2, doi:10.21105/joss.00139, 2017. [cited by applicant]
Karim et al. Synthetic Biology 2020; 5(1): ysaa019. [cited by applicant]
Köpke, Curr Opin Biotechnol, 22: 320-325, 2011. [cited by applicant]
Liu et al. “Predicting proteome allocation, overflow metabolism, and metal requirements in a model acetogen” PLoS PLOS Computational Biology 15(3): e1006848. pp. 1-16, Mar. 7, 2019 https://doi.org/10.1371/journal.pcbi.1… [cited by applicant]
Maia, Proceedings of the Genetic and Evolutionary Computation Conference Companion on—GECCO '17, New York, New York, ACM Press, 1661-1668, 2017. [cited by applicant]
Marcellin, Green Chem, 18: 3020-3028, 2016. [cited by applicant]
OBrien et al. “Using Genome-scale Models to Predict Biological Capabilities” Cell, vol. 161, Issue 5, pp. 971-987, May 21, 2015. https://doi.org/10.1016/j.cell.2015.05.019. [cited by applicant]
Perez, Biotechnol Bioeng, 110:1066-1077, 2012. [cited by applicant]
Ragsdale, Biochim Biophys Acta, 1784: 1873-1898, 2008. [cited by applicant]
Ruano-Gallego et al., “Screening and purification of nanobodies from [cited by applicant]
Schmidt, Protein Expr Purif 92: 54-61, 2013. [cited by applicant]
Sonnenschein et al., “Biosustain/Cameo: 0.11.0,” Zenodo, Jul. 28, 2017, 5 pages. doi:10.5281/zenodo.835730. [cited by applicant]
Tanner, Int J System Bacteriol, 43: 232-236, 1993. [cited by applicant]
Thiele, Nature Protocols, 5: 93-121, 2010. [cited by applicant]
Tirado-Acevedo, Production of bioethanol from synthesis gas using Clostridium ljungdahlii, PhD thesis, North Carolina State University, 2010. [cited by applicant]